- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 12.05. | AstraZeneca's $800M bet undermined by immunogenicity in phase 3 | ||
| 12.05. | Bayer scraps protein therapy for hypertension from phase 1, along with neuropathic pain drug | ||
| 12.05. | Bristol Myers Squibb inks $15B biobucks deal to bag Hengrui assets, tap China's R&D speed | ||
| 11.05. | Amid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data | ||
| 08.05. | Analysts cut enGene cancer sales forecast after updated data widen gap to J&J | ||
| 08.05. | Odyssey voyages to Nasdaq with $304M IPO to fund autoimmune, inflammatory pipeline | ||
| 07.05. | BeOne shelves 5 cancer programs, halts phase 2 rheumatoid arthritis trial | ||
| 07.05. | Blackstone invests $250M in Anagram to reduce burden of cystic fibrosis complication | ||
| 07.05. | Ascendis axes IL-2 program in retreat from oncology expansion | ||
| 07.05. | Entrada's stock craters as DMD data underperform expectations, handing advantage to Novartis | ||
| 07.05. | From drug development to M&A, Big Pharmas showcase AI's 'measurable impact' | ||
| 06.05. | Ipsen scuttles liver disease candidates from $952M Albireo acquisition | ||
| 06.05. | BioCryst scraps eye candidate to focus on rare diseases | ||
| 06.05. | GSK pens $1B deal with China's SiranBio for oligonucleotide that could reduce abdominal fat | ||
| 06.05. | Bayer buys Perfuse in $2.4B deal for midphase eye disease prospect | ||
| 06.05. | Avalo's phase 2 skin disease win fuels pursuit of AbbVie despite placebo headwind | ||
| 06.05. | Novo CEO insists 'no change in plan' for CagriSema launch after single-chamber device ditched | ||
| 05.05. | After Arcellx buyout close, Gilead trims 108 jobs at CAR-T biotech's Redwood City outpost | ||
| 05.05. | Madrigal continues MASH deal spree with $1B biobucks license for Arrowhead asset rejected by J&J | ||
| 05.05. | Pfizer's $2.3B Trillium bet ends in failure as remaining CD47 blocker scrapped along with T-cell engager | ||
| 05.05. | Viridian's Tepezza rival racks up second phase 3 win, clearing path to FDA | ||
| 04.05. | Passage launches strategic review and 75% layoffs after gene therapy path blocked by FDA | ||
| 04.05. | Takeda pivotal trial win improves convenience for PID patients relative to HyQvia | ||
| 04.05. | Mirum maps FDA path after anti-itch candidate scores ph. 2 win | ||
| 04.05. | Windward catches $165M breeze to fuel long-acting TSLP ambitions |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.